# A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

> **NCT04732221** · PHASE2,PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 168 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension
- Hypertension, Pulmonary

## Interventions

- **DRUG:** Frespaciguat
- **DRUG:** Placebo to Frespaciguat

## Key facts

- **NCT ID:** NCT04732221
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-19
- **Primary completion:** 2024-01-04
- **Final completion:** 2024-07-02
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04732221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04732221, "A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04732221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*